Analyst Ratings For AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
Today, B. Riley reiterated its Buy rating on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) with a price target of $20.50.
There are 7 Hold Ratings, 2 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is Hold with a consensus target price of $20.9150 per share, a potential 23.32% upside.
Some recent analyst ratings include
- 12/14/2018-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its Buy ➝ Buy rating reiterated by B. Riley with a $20.50 price target
- 11/23/2018-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its Neutral rating reiterated by Cantor Fitzgerald
- 11/6/2018-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) gets downgraded to Underweight by JPMorgan Chase & Co. with a price target of $18.00
- 8/3/2018-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its Hold rating reiterated by Jefferies Financial Group with a $22.00 price target
- 6/15/2018-AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) gets downgraded to Neutral by Janney Montgomery Scott with a price target of $20.00
- On 8/7/2018 William K Heiden, CEO, sold 5,000 with an average share price of $25.00 per share and the total transaction amounting to $125,000.00.
- On 6/4/2018 William K Heiden, CEO, sold 20,000 with an average share price of $25.00 per share and the total transaction amounting to $500,000.00.
- On 3/6/2018 Joseph Vittiglio, EVP, sold 770 with an average share price of $20.80 per share and the total transaction amounting to $16,016.00.
- On 8/29/2017 Joseph Vittiglio, SVP, sold 1,250 with an average share price of $16.75 per share and the total transaction amounting to $20,937.50.
- On 7/13/2017 Julie Krop, SVP, sold 4,938 with an average share price of $20.00 per share and the total transaction amounting to $98,760.00.
- On 5/1/2017 Julie Krop, SVP, sold 1,891 with an average share price of $24.45 per share and the total transaction amounting to $46,234.95.
- On 10/20/2016 Julie Krop, SVP, sold 4,938 with an average share price of $24.80 per share and the total transaction amounting to $122,462.40.
About AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases.Its products include Intrarosa, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
Recent Trading Activity for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
Shares of AMAG Pharmaceuticals, Inc. closed the previous trading session at 17,08 +0,090 0,53 % with 16.32 shares trading hands.